Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis (Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases)

Veterinary Dermatology

Volumn 25, Issue 3, 2014, Pages

  Hillier, Andrew ^a   Lloyd, David H ^b   Weese, J Scott ^c   Blondeau, Joseph M ^d   Boothe, Dawn ^e   Breitschwerdt, Edward ^f   Guardabassi, Luca ^g   Papich, Mark G ^f   Rankin, Shelley ^h   Turnidge, John D ⁱ   Sykes, Jane E ^j  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b ROYAL VETERINARY COLLEGE   (United Kingdom)

^c UNIVERSITY OF GUELPH   (Canada)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e AUBURN UNIVERSITY   (United States)

^f NORTH CAROLINA STATE UNIVERSITY   (United States)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

ⁱ WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ANIMAL; DOG; DOG DISEASES; FOLLICULITIS; SKIN DISEASES, BACTERIAL; VETERINARY;

ANIMALS; ANTI-BACTERIAL AGENTS; DOG DISEASES; DOGS; FOLLICULITIS; SKIN DISEASES, BACTERIAL;

EID: 84900863583     PISSN: 09594493     EISSN: 13653164     Source Type: Journal    
DOI: 10.1111/vde.12118     Document Type: Article

References (76)

1. Guardabassi L, Houser GA, Frank LA et al. Guidelines for antimicrobial use in dogs and cats. In: Guardabassi L, Jensen LB, Kruse H, eds. Guide to Antimicrobial use in Animals. Oxford: Blackwell Publishing, 2008; 182-206.
2. Edn Rantala M, Hölsö K, Lillas A et al. Survey of condition-based prescribing of antimicrobial drugs for dogs at a veterinary teaching hospital. Vet Rec 2004; 155: 259-262.
3. Baker SA, Van-Balen J, Lu B et al. Antimicrobial drug use in dogs prior to admission to a veterinary teaching hospital. J Am Vet Med Assoc 2012; 241: 210-217.
4. Deuster S, Roten I, Muehlebach S. Implementation of treatment guidelines to support judicious use of antibiotic therapy. J Clin Pharm Ther 2010; 35: 71-78.
5. Metjian TA, Prasad PA, Kogon A et al. Evaluation of an antimicrobial stewardship program at a pediatric teaching hospital. Pediatr Infect Dis J 2008; 27: 106-111.
6. Toth NR, Chambers RM, Davis SL. Implementation of a care bundle for antimicrobial stewardship. Am J Health Syst Pharm 2010; 67: 746-749.
7. Beco L, Guaguère E, Lorente Méndez C et al. Suggested guidelines for using systemic antimicrobials in bacterial skin infections: part 2-antimicrobial choice, treatment regimens and compliance. Vet Rec 2013; 172: 156-160.
8. Devriese LA, Vancanneyt M, Baele M et al. Staphylococcus pseudintermedius sp. nov., a coagulase-positive species from animals. Int J Syst Evol Microbiol 2005; 55: 1569-1573.
9. Frank LA, Kania SA, Hnilic KA et al. Isolation of Staphylococcus schleiferi from dogs with pyoderma. J Am Vet Med Assoc 2003; 222: 451-454.
10. Cain CL, Morris DO, O'Shea K et al. Genotypic relatedness and phenotypic characterization of Staphylococcus schleiferi subspecies in clinical samples from dogs. Am J Vet Res 2011; 72: 96-102.
11. Fortin M, Higgins R. Mixed infection associated with a group B Streptococcus in a dog. Can Vet J 2001; 42: 730.
12. Hillier A, Alcorn JR, Cole LK et al. Pyoderma caused by Pseudomonas aeruginosa infection in dogs: 20 cases. Vet Dermatol 2006; 17: 432-439.
13. Mendelsohn C, Rosenkrantz W, Griffin CE. Practical cytology for inflammatory skin diseases. Clin Tech Small Anim Pract 2006; 21: 117-127.
14. Miller WH, Griffin CE, Campbell KL. Muller & Kirk's Small Animal Dermatology. 7thedition. St Louis, MO: Elsevier, 2013; 191.
15. Toma S, Colombo S, Cornegliani L et al. Efficacy and tolerability of once-daily cephalexin in canine superficial pyoderma: an open controlled study. J Small Anim Pract 2008; 49: 384-391.
16. Miller WH, Griffin CE, Campbell KL. Muller & Kirk's Small Animal Dermatology. 7th edition. St Louis, MO: Elsevier, 2013; 195.
17. Frank LA, Kunkle GA. Comparison of the efficacy of cefadroxil and generic and proprietary cephalexin in the treatment of pyoderma in dogs. J Am Vet Med Assoc 1993; 203: 530-533.
18. Harvey RG, Noble WC, Ferguson EA. A comparison of lincomycin hydrochloride and clindamycin hydrochloride in the treatment of superficial pyoderma in dogs. Vet Rec 1993; 132: 351-353.
19. Littlewood JD, Lakhani KH, Paterson S et al. Clindamycin hydrochloride and clavulanate-amoxycillin in the treatment of canine superficial pyoderma. Vet Rec 1999; 144: 662-665.
20. Lloyd DH, Carlotti DN, Koch HJ et al. Treatment of canine pyoderma with co-amoxyclav: a comparison of two dose rates. Vet Rec 1997; 141: 439-441.
21. Messinger LM, Beale KM. A blinded comparison of the efficacy of daily and twice daily trimethoprim-sulfadiazine and daily sulfadimethoxine-ormetoprim in the treatment of canine pyoderma. Vet Dermatol 1993; 4: 13-18.
22. Bloom PB, Rosser EJ. Efficacy of once-daily clindamycin hydrochloride in the treatment of superficial bacterial pyoderma in dogs. J Am Anim Hosp Assoc 2001; 37: 537-542.
23. Soares Magalhães RJ, Loeffler A, Lindsay J et al. Risk factors for methicillin-resistant Staphylococcus aureus (MRSA) infection in dogs and cats: a case-control study. Vet Res 2010; 41: 55.
24. Nienhoff U, Kadlec K, Chaberny IF et al. Methicillin-resistant Staphylococcus pseudintermedius among dogs admitted to a small animal hospital. Vet Microbiol 2011; 150: 191-197.
25. Weese JS, Faires MC, Frank LA et al. Factors associated with methicillin-resistant versus methicillin-susceptible Staphylococcus pseudintermedius infection in dogs. J Am Vet Med Assoc 2012; 240: 1450-1455.
26. Beck KM, Waisglass SE, Dick HL et al. Prevalence of meticillin-resistant Staphylococcus pseudintermedius (MRSP) from skin and carriage sites of dogs after treatment of their meticillin-resistant or meticillin-sensitive staphylococcal pyoderma. Vet Dermatol 2012; 23: 369-375.
27. van Duijkeren E, Kamphuis M, van der Mije IC et al. Transmission of methicillin-resistant Staphylococcus pseudintermedius between infected dogs and cats and contact pets, humans and the environment in households and veterinary clinics. Vet Microbiol 2011; 150: 338-343.
28. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals; Approved Standard - 3rd edition. CLSI document M31-A3. Wayne, PA: CLSU, 2008.
29. Steward CD, Raney P, Morrell A et al. Testing for induction of clindamycin resistance in erythromycin-resistant isolates of Staphylococcus aureus. J Clin Microbiol 2005; 43: 1716-1721.
30. Bannoehr J, Guardabassi L. Staphylococcus pseudintermedius in the dog: taxonomy, diagnostics, ecology, epidemiology and pathogenicity. Vet Dermatol 2012; 23: 253-266.
31. Jousson O, Di Bello D, Vanni M et al. Genotypic versus phenotypic identification of staphylococcal species of canine origin with special reference to Staphylococcus schleiferi subsp. coagulans. Vet Microbiol 2007; 123: 238-244.
32. Zdovc I, Ocepek M, Pirš T. Microbiological features of Staphylococcus schleiferi subsp. coagulans isolated from dogs and possible misidentification with other canine coagulase-positive staphylococci. J Vet Med B Infect Dis Vet Public Health 2004; 51: 449-454.
33. de Jaham C. Effects of an ethyl lactate shampoo in conjunction with a systemic antibiotic in the treatment of canine superficial bacterial pyoderma in an open-label, nonplacebo-controlled study. Vet Ther 2003; 4: 94-100.
34. Loeffler A, Baines S, Toleman M et al. In vitro activity of fusidic acid and mupirocin against coagulase-positive staphylococci from pets. J Antimicrob Chemother 2008; 62: 1301-1304.
35. Loeffler A, Linek M, Moodley A et al. First report of multiresistant, mecA-positive Staphylococcus intermedius in Europe: 12 cases from a veterinary dermatology referral clinic in Germany. Vet Dermatol 2007; 18: 412-421.
36. Mueller RS, Bergvall K, Bensignor E et al. A review of topical therapy for skin infections with bacteria and yeast. Vet Dermatol 2012; 23: 330-341.
37. Summers JF, Brodbelt DC, Forsythe PJ et al. The effectiveness of systemic antimicrobial treatment in canine superficial and deep pyoderma: a systematic review. Vet Dermatol 2012; 23: 305-327.
38. Werckenthin C, Cardoso M, Martel J-M et al. Antimicrobial resistance in staphylococci from animals with particular reference to bovine Staphylococcus aureus, porcine Staphylococcus hyicus, and canine Staphylococcus intermedius. Vet Res 2001; 32: 341-362.
39. Frank LA, Loeffler A. Meticillin-resistant Staphylococcus pseudintermedius: clinical challenge and treatment options. Vet Dermatol 2012; 23: 283-291.
40. Guaguère E, Salomon C, Maynard L. Using cephalexin in the treatment of canine pyoderma. Comparing the efficacy of different dosage. Pract Med Chirurg Anim Comp 1998; 33: 237-246.
41. Cherni JA, Boucher JF, Skogerbo TL et al. Comparison of the efficacy of cefpodoxime proxetil and cephalexin in treating bacterial pyoderma in dogs. Int J Appl Res Vet Med 2006; 4: 85-93.
42. Stegemann MR, Coati N, Passmore CA et al. Clinical efficacy and safety of cefovecin in the treatment of canine pyoderma and wound infections. J Small Anim Pract 2007; 48: 378-386.
43. Six R, Cherni J, Chesebrough R et al. Efficacy and safety of cefovecin in treating bacterial folliculitis, abscesses or infected wounds in dogs. J Am Vet Med Assoc 2008; 233: 433-439.
44. Stegemann MR, Sherington J, Blanchflower S. Pharmacokinetics and pharmacodynamics of cefovecin in dogs. J Vet Pharmacol Ther 2006; 29: 501-511.
45. ® (cefovecin sodium). Pfizer Animal Health. Revised June 2011.
46. ® (cefpodoxime proxetil). Pfizer. NADA #141-232
47. Rota A, Milani C, Corrò M et al. Misuse of antimicrobials and selection of methicillin-resistant Staphylococcus pseudintermedius strains in breeding kennels: genetic characterization of bacteria after a two-year interval. Reprod Domest Anim 2012; 48: 1-6.
48. Crowcroft NS, Ronveaux O, Monnet DL et al. Methicillin-resistant Staphylococcus aureus and antimicrobial use in Belgian hospitals. Infect Control Hosp Epidemiol 1999; 20: 31-36.
49. Hori S, Sunley R, Tami A et al. The Nottingham Staphylococcus aureus population study: prevalence of MRSA among the elderly in a university hospital. J Hosp Infect 2002; 50: 25-29.
50. Taconelli E, De Angelis G, Cataldo MA et al. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis J Antimicrob Chemother 2008; 61: 26-38.
51. Faires MC, Traverse M, Tater KC et al. Methicillin-resistant and -susceptible Staphylococcus aureus infections in dogs. Emerg Infect Dis 2010; 16: 69-75.
52. Cavaco LM, Abatih E, Aarestrup FM et al. Selection and persistence of CTX-M-producing Escherichia coli in the intestinal flora of pigs treated with amoxicillin, ceftiofur, or cefquinome. Antimicrob Agents Chemother 2008; 52: 3612-3616.
53. Birgy A, Cohen R, Levy C et al. Community faecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae in French children. BMC Infect Dis 2012; 12: 315.
54. Snow LC, Warner RG, Cheney T et al. Risk factors associated with extended spectrum beta-lactamase Escherichia coli (CTX-M) on dairy farms in North West England and North Wales. Prev Vet Med 2012; 106: 225-234.
55. Tinelli M, Cataldo MA, Mantengoli E et al. Epidemiology and genetic characteristics of extended-spectrum β-lactamase-producing Gram-negative bacteria causing urinary tract infections in long-term care facilities. J Antimicrob Chemother 2012; 67: 2982-2987.
56. Coia JE, Duckworth GJ, Edwards DI et al. Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J Hosp Infect 2006; 63S: S1-S44.
57. Byrne FM, Wilcox MH. MRSA prevention strategies and current guidelines. Injury 2011; 42 (Suppl. 5): S3-S6.
58. Muto CA, Jurnigan JA, Ostrowsky BE et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003; 24: 362-386.
59. Convenia Technical Monograph. Walton Oaks, Walton on the Hill, Surrey: Pfizer Animal Health UK, 2006; 32.
60. Bryan J, Frank L, Rohrbach B et al. Treatment outcome of dogs with methicillin-resistant and methicillin-susceptible Staphylococcus pseudintermedius pyoderma. Vet Dermatol 2012; 23: 361-368.
61. Kwochka K. Recurrent pyoderma. In: Griffin CE, Kwochka KW, McDonald JM eds. Current Veterinary Dermatology. St Louis, MO: Mosby Yearbook, 1993; 3-21.
62. Carlotti DN, Jasmin P, Gardey L et al. Evaluation of cephalexin intermittent therapy (weekend therapy) in the control of recurrent idiopathic pyoderma in dogs: a randomized, double-blinded, placebo-controlled study. In: Hillier A, Foster AP, Kwochka KW, eds. Advances in Veterinary Dermatology. Volume 5. Oxford: Blackwell Publishing 2005; 137-146.
63. Curtis CF, Lamport AI, Lloyd DH. Masked, controlled study to investigate the efficacy of a Staphylococcus intermedius autogenous bacterin for the control of canine idiopathic recurrent superficial pyoderma. Vet Dermatol 2006; 17: 163-168.
64. DeBoer DJ, Moriello KA, Thomas CB et al. Evaluation of a commercial staphylococcal bacterin for management of idiopathic recurrent pyoderma in dogs. Am J Vet Res 1990; 51: 636-639.
65. Tacconelli E, Johnson AP. National guidelines for decolonization of methicillin-resistant Staphylococcus aureus carriers: the implications of recent experience in the Netherlands. J Antimicrob Chemother 2011; 66: 2195-2198.
66. Fritz SA, Camins BC, Eisenstein KA et al. Effectiveness of measures to eradicate Staphylococcus aureus carriage in patients with community-associated skin and soft-tissue infections: a randomized trial. Infect Control Hosp Epidemiol 2011; 32: 872-880.
67. Loeffler A, Lloyd DH. Companion animals: a reservoir for methicillin-resistant Staphylococcus aureus in the community? Epidemiol Infect 2010; 138: 595-605.
68. Stegmann R, Burnens A, Maranta CA et al. Human infection associated with methicillin-resistant Staphylococcus pseudintermedius ST71. J Antimicrob Chemother 2010; 65: 2047-2048.
69. Riegel P, Jesel-Morel L, Laventie B et al. Coagulase-positive Staphylococcus pseudintermedius from animals causing human endocarditis. Int J Med Microbiol 2011; 301: 237-239.
70. Cohn LA, Middleton JR. A veterinary perspective on methicillin-resistant staphylococci. J Vet Emerg Crit Care (San Antonio) 2010; 20: 31-45.
71. Federation of European Companion Animal Veterinary Associations (FECAVA) poster on Key recommendations for hygiene and infection control in veterinary practice. http://www.fecava.org/sites/default/files/files/FECAVA%20Key%20recommodation%20for%20Hygiene%20and%20Infection%20Control.pdf Accessed 4 November 2013.
72. British Small Animal Veterinary Association (BSAVA) Hygiene recommendations. http://www.bsava.com/Advice/MRSA/tabid/171/Default.aspx. Accessed 24 February 2013.
73. Weese JS. Staphylococcal control in the veterinary hospital. Vet Dermatol 2012; 23: 292-298.
74. White SD, Brown AE, Chapman PL et al. Evaluation of aerobic bacteriologic culture of epidermal collarette specimens in dogs with superficial pyoderma. J Am Vet Med Assoc 2005; 226: 904-908.
75. Kadlec K, van Duijkeren E, Wagenaar JA et al. Molecular basis of rifampicin resistance in methicillin-resistant Staphylococcus pseudintermedius isolates from dogs. J Antimicrob Chemother 2011; 66: 1236-1242.
76. Papich M. Ciprofloxacin pharmacokinetics and oral absorption of generic ciprofloxacin tablets in dogs. Am J Vet Res 2012; 73: 1085-1091.